{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:38:00Z","timestamp":1790872680752,"version":"4.1.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1093\/ndt\/gfs526","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T01:38:13Z","timestamp":1355362693000},"page":"505-517","source":"Crossref","is-referenced-by-count":81,"title":["Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice"],"prefix":"10.1093","volume":"28","author":[{"given":"Wim","family":"Terryn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"key\n\t\t\t\t20170518090108_GFS526C1","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/ndt\/gfn238","article-title":"European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP)","volume":"23","author":"Zoccali","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry's disease: alpha-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"key\n\t\t\t\t20170518090108_GFS526C4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease\u2014ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C6","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170518090108_GFS526C7"},{"key":"key\n\t\t\t\t20170518090108_GFS526C8","volume-title":"The Metabolic & Molecular Bases of Inherited Disease","author":"Scriver"},{"key":"key\n\t\t\t\t20170518090108_GFS526C9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"Scheidt von","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u2018renal variant\u2019 phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170518090108_GFS526C12","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","article-title":"Identification of fifteen novel mutations and genotype\u2013phenotype relationship in Fabry disease","volume":"60","author":"Altarescu","year":"2001","journal-title":"Clin Genet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","article-title":"Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers","volume":"353","author":"Linthorst","year":"2005","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20170518090108_GFS526C16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20170518090108_GFS526C19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170518090108_GFS526C21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study\u2014screening genetic conditions in PORTuguese young STROKE patients","volume":"41","author":"Baptista","year":"2010","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170518090108_GFS526C22","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20170518090108_GFS526C25","article-title":"Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy","author":"Terryn","year":"2012 15. [ ]","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cca.2009.02.008","article-title":"Effect of sample collection on \u03b1-galactosidase A enzyme activity measurements in dried blood spots on filter paper","volume":"403","author":"Olivova","year":"2009","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20170518090108_GFS526C28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2010","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170518090108_GFS526C29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380030204","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20170518090108_GFS526C30","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-481-9033-1","volume-title":"Fabry Disease","author":"Elstein","year":"2010"},{"key":"key\n\t\t\t\t20170518090108_GFS526C31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease\u2014recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.ajkd.2010.10.046","article-title":"Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study","volume":"57","author":"Paschke","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20170518090108_GFS526C35","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20170518090108_GFS526C36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Togawa","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20170518090108_GFS526C37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20170518090108_GFS526C38","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1093\/ndt\/gfr084","article-title":"Targeted urine microscopy in Anderson\u2013Fabry disease: a cheap, sensitive and specific diagnostic technique","volume":"26","author":"Selvarajah","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2010","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518090108_GFS526C41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C42","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C43","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/01913123.2010.538136","article-title":"Unexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function","volume":"35","author":"Kochar","year":"2011","journal-title":"Ultrastruct Pathol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00109-010-0686-2","article-title":"ACE activity is modulated by the enzyme \u03b1-galactosidase A","volume":"89","author":"Batista","year":"2010","journal-title":"J Mol Med"},{"key":"key\n\t\t\t\t20170518090108_GFS526C48","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20170518090108_GFS526C49","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2215\/CJN.02010309","article-title":"Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD","volume":"4","author":"Agarwal","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C52","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson\u2013Fabry disease","author":"Dib El","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170518090108_GFS526C53","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C55","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C56","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518090108_GFS526C57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2014the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20170518090108_GFS526C58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C61","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518090108_GFS526C62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20170518090108_GFS526C64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20170518090108_GFS526C65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"Suppl B","key":"key\n\t\t\t\t20170518090108_GFS526C66","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0149-2918(08)80041-0","article-title":"The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative","volume":"30","author":"Schellekens","year":"2008","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170518090108_GFS526C67","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C68","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090108_GFS526C69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518090108_GFS526C70","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease","volume":"22","author":"Pastores","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518090108_GFS526C72","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518090108_GFS526C73","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1016\/j.transproceed.2005.11.021","article-title":"Kidney transplantation improves survival and is indicated in Fabry's disease","volume":"37","author":"Inderbitzin","year":"2005","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20170518090108_GFS526C74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","article-title":"Kidney transplant outcomes in patients with Fabry disease","volume":"87","author":"Shah","year":"2009","journal-title":"Transplantation"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/3\/505\/17171561\/gfs526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:24:40Z","timestamp":1562459080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfs526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,12,12]]},"published-print":{"date-parts":[[2013,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfs526","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}